Find Nivolumab manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

49 RELATED EXCIPIENT COMPANIES

96EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set

API SUPPLIERS

read-more
read-more

01

LGM Pharma

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
LGM Pharma CB

02

Shanghai Minbiotech

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
World Vaccine Congress
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Shanghai Minbiotech CB

03

Nanogen Pharmaceutical Biotechnolo...

Vietnam

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

World Vaccine Congress
Not Confirmed
arrow

04

KinBio

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

World Vaccine Congress
Not Confirmed
arrow

KinBio

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
World Vaccine Congress
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Parenteral

read-more
read-more

Direct Compression

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Solubilizers

read-more
read-more

Taste Masking

read-more
read-more

Co-Processed Excipients

read-more
read-more

Emulsifying Agents

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Granulation

read-more
read-more

Topical

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Controlled & Modified Release

read-more
read-more

API Stability Enhancers

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Rheology Modifiers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Annual Reports

read-more
read-more

01

Brand Name : Opdivo

Nivolumab

arrow
SupplySide West 2024
Not Confirmed

Brand Name : Opdivo

U.S.A
arrow
SupplySide West 2024
Not Confirmed

Nivolumab

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 6,992

2019 Revenue in Millions : 7,204

Growth (%) : -3

blank

02

Brand Name : Opdivo

Nivolumab

arrow
SupplySide West 2024
Not Confirmed

Brand Name : Opdivo

Japan
arrow
SupplySide West 2024
Not Confirmed

Nivolumab

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 907

2019 Revenue in Millions : 827

Growth (%) : 10

blank

03

Brand Name : Opdivo

Nivolumab

arrow
SupplySide West 2024
Not Confirmed

Brand Name : Opdivo

U.S.A
arrow
SupplySide West 2024
Not Confirmed

Nivolumab

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 7,523

2020 Revenue in Millions : 6,992

Growth (%) : 8

blank

04

Brand Name : Opdivo

Nivolumab

arrow
SupplySide West 2024
Not Confirmed

Brand Name : Opdivo

Japan
arrow
SupplySide West 2024
Not Confirmed

Nivolumab

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 908

2020 Revenue in Millions : 870

Growth (%) : 12

blank

05

Brand Name : Opdualag

Nivolumab

arrow
SupplySide West 2024
Not Confirmed

Brand Name : Opdualag

U.S.A
arrow
SupplySide West 2024
Not Confirmed

Nivolumab

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 252

2021 Revenue in Millions : 0

Growth (%) : New Launch in 2022

blank

06

Brand Name : Opdivo

Nivolumab

arrow
SupplySide West 2024
Not Confirmed

Brand Name : Opdivo

Japan
arrow
SupplySide West 2024
Not Confirmed

Nivolumab

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 1,050

2021 Revenue in Millions : 908

Growth (%) : 16

blank

07

Brand Name : Opdivo

Nivolumab

arrow
SupplySide West 2024
Not Confirmed

Brand Name : Opdivo

U.S.A
arrow
SupplySide West 2024
Not Confirmed

Nivolumab

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 8,249

2021 Revenue in Millions : 7,523

Growth (%) : 10

blank

08

Brand Name : Opdivo

Nivolumab

arrow
SupplySide West 2024
Not Confirmed

Brand Name : Opdivo

U.S.A
arrow
SupplySide West 2024
Not Confirmed

Nivolumab

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 9,009

2022 Revenue in Millions : 8,249

Growth (%) : 9

blank

09

Brand Name : Opdualag

Nivolumab/Relatlimab-rmbw

arrow
SupplySide West 2024
Not Confirmed

Brand Name : Opdualag

U.S.A
arrow
SupplySide West 2024
Not Confirmed

Nivolumab/Relatlimab-rmbw

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 627

2022 Revenue in Millions : 252

Growth (%) : 149

blank

10

Brand Name : Opdivo

Nivolumab

arrow
SupplySide West 2024
Not Confirmed

Brand Name : Opdivo

Japan
arrow
SupplySide West 2024
Not Confirmed

Nivolumab

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 1,001

2022 Revenue in Millions : 1,050

Growth (%) : 8

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty